Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
npx887
- Development stage
- Phase 1
- Lead developer
- NextPoint Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NPX887 is a fully human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody developed by NextPoint Therapeutics for the treatment of solid tumors. It targets HHLA2 (also known as B7-H7), a novel immune checkpoint and tumor antigen highly expressed in many cancers independently of PD-L1. By binding to HHLA2, NPX887 blocks its interaction with killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3), thereby inhibiting KIR3DL3-mediated immunosuppression and preventing immune escape in solid tumors. This mechanism is believed to promote T cell and natural killer (NK) cell antitumor activity within the tumor microenvironment. The drug is currently being evaluated in Phase 1 clinical trials for multiple solid tumor types, including non-small cell lung carcinoma (NSCLC), small cell lung carcinoma (SCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), and other malignancies expressing HHLA2/B7-H7[1][2][5][6][8].
- Other names
- anti-HHLA2 monoclonal antibody NPX887anti-HHLA-2 monoclonal antibody NPX887anti-HHLA 2 monoclonal antibody NPX887anti-B7-H7 monoclonal antibody NPX887anti-B-7-H7 monoclonal antibody NPX887anti-B 7-H7 monoclonal antibody NPX887
02
Targets
HHLA2 (HERV-H LTR-associating protein 2)KIR3DL3 (Killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 3)
Beyond the preview
Go deeper on npx887.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on npx887.